Miruvor
Sign up
The short answer

What studies of Amisulpride (Solian) found

1paper on Amisulpride (Solian)
40people in 1 study testing Amisulpride (Solian) alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: B May help

Based on the strongest evidence, the randomised trial (low certainty), for overall symptoms.

5 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Amisulpride (Solian) may help for ME/CFS, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 1 paper.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Amisulpride (Solian) · ME/CFS is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Fatigue1 study · 40 people took Amisulpride (Solian) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 1.92 (large).

The randomised trial40 randomised · 12 weeks · 25 mg, bid

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of amisulpride (Solian) on fatigue in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (40 in all)
  • Effect size 1.92 (large)

How big was the difference?

1.92, large. The effect size compares Amisulpride (Solian) with fluoxetine group.

See the 1 study
  1. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)

    People in the study
    40 randomised
    Dose
    25 mg, bid
    Outcome
    FSS Krupp Fatigue Severity Scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Pain1 study · 40 people took Amisulpride (Solian) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 1.25 (large).

The randomised trial40 randomised · 12 weeks · 25 mg, bid

Pain improved more than in the comparison group.

The evidence is very uncertain about the effect of amisulpride (Solian) on pain in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (40 in all)
  • Effect size 1.25 (large)

How big was the difference?

1.25, large. The effect size compares Amisulpride (Solian) with fluoxetine group.

See the 1 study
  1. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)

    People in the study
    40 randomised
    Dose
    25 mg, bid
    Outcome
    VAS-pain visual analog scale
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 40 people took Amisulpride (Solian) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out; effect size 0.23 (small).

The randomised trial40 randomised · 12 weeks · 25 mg, bid

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of amisulpride (Solian) on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 40 people found no clear difference; a small benefit can't be ruled out
  • Effect size 0.23 (small)

How big was the difference?

0.23, small. The effect size compares Amisulpride (Solian) with fluoxetine group.

See the 1 study
  1. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)

    People in the study
    40 randomised
    Dose
    25 mg, bid
    Outcome
    HADS-D Hospital Anxiety and Depression Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Daily life and health overall

Overall symptoms1 study · 40 people took Amisulpride (Solian) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (40 in all); effect size 1.63 (large).

The randomised trial40 randomised · 12 weeks · 25 mg, bid

Overall symptoms improved more than in the comparison group.

Amisulpride (Solian) may improve overall symptoms in ME/CFS. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (40 in all)
  • Effect size 1.63 (large)

How big was the difference?

1.63, large. The effect size compares Amisulpride (Solian) with fluoxetine group.

See the 1 study
  1. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)

    People in the study
    40 randomised
    Dose
    25 mg, bid
    Outcome
    CGI-S Clinical Global Impression Severity
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Quality of life1 study · 40 people took Amisulpride (Solian) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 2.62 (large).

The randomised trial40 randomised · 12 weeks · 25 mg, bid

Quality of life improved more than in the comparison group.

The evidence is very uncertain about the effect of amisulpride (Solian) on quality of life in ME/CFS. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (40 in all)
  • Effect size 2.62 (large)

How big was the difference?

2.62, large. The effect size compares Amisulpride (Solian) with fluoxetine group.

See the 1 study
  1. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)

    People in the study
    40 randomised
    Dose
    25 mg, bid
    Outcome
    SF-12 Short-Form 12-Item Health Survey
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Side effects

Stopping because of side effects1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    25 mg at the start

  2. 2Top dose

    Most often 25 mg (1 of 1 studies)

Doses across 1 study

25 to 25 mg.

Each study’s dose, as printed

All papers

  1. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study.2011 · randomised trial · 40 randomised
    Summary

    This pilot study asked whether low-dose amisulpride would improve symptoms in non-depressed chronic fatigue syndrome (CFS) compared with an SSRI. Forty patients at a single centre, enrolled through clinician referrals and self-referrals, were randomised to amisulpride 25 mg bid. or fluoxetine 20 mg uid. for twelve weeks; all subjects completed the planned 12-week therapy period and were un-blinded to treatment. Fatigue (Krupp Fatigue Severity Scale, FSS), anxiety and depression (HADS), pain and bodily discomfort (VAS-pain), quality of life (SF-12) and clinician-rated severity (CGI-S) were assessed at enrolment and after twelve weeks; side effects were assessed with FIBSER at twelve weeks. After twelve weeks, amisulpride-treated patients had lower FSS scores (36.3 ± 8.6 vs. 48.9 ± 4.9; p = 0.001), lower VAS-pain scores (40.5 ± 13.1 vs. 53.1 ± 8.3; p = 0.01), higher SF-12 scores (53.2 ± 4.8 vs. 37.6 ± 4.9; p = 0.01) and lower CGI-S scores (2.9 ± 0.6 vs. 4.2 ± 1.1; p = 0.005) than fluoxetine-treated patients. HADS-D (4.1 ± 0.9 vs. 4.3 ± 0.9; p = 0.6) and HADS-A (4.5 ± 1.0 vs. 4.9 ± 1.0; p = 0.6) did not differ between groups. Within the amisulpride group, FSS, VAS-pain, CGI-S and SF-12 changed significantly (p = 0.001 for each), while HADS-A (p = 0.14) and HADS-D (p = 0.1) did not. Within the fluoxetine group, HADS-D fell significantly (p = 0.009); FSS (p = 0.1), VAS-pain (p = 0.09), CGI-S (p = 0.1), SF-12 (p = 0.1) and HADS-A (p = 0.8) did not change significantly. FIBSER frequency, intensity and burden did not differ between groups (p = 0.6, p = 0.9, p = 0.6), and both drugs were equally well tolerated.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime